KYMR

Kymera Therapeutics Inc

KYMR, USA

Kymera Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa and atopic dermatitis. The company also develops STAT6, a type 2 inflammation in allergic and atopic diseases; and TYK2 to treat autoimmune and inflammatory diseases. The company has a strategic alliance with Sanofi S.A. for the development of drug candidates targeting IRAK4 outside of the oncology and immuno-oncology fields. Kymera Therapeutics, Inc. was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

https://www.kymeratx.com

Stock Price

$ 0.00

0% increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
KYMR
stock
KYMR

Kymera Therapeutics (NASDAQ:KYMR) Director Bruce Booth Sells 678 Shares MarketBeat

Read more →
KYMR
stock
KYMR

Insider Selling: Kymera Therapeutics (NASDAQ:KYMR) Director Sells 6,101 Shares of Stock MarketBeat

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

STRONG BUY

Target Price:

$77.5909

Analyst Picks

Strong Buy

14

Buy

3

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very High

8.27

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

-8.68 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-7.46 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

-987.37 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very High

0.16

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 118.76% of the total shares of Kymera Therapeutics Inc

1.

T. Rowe Price Associates, Inc.

(9.5936%)

since

2025/06/30

2.

Baker Bros Advisors LP

(9.303%)

since

2025/06/30

3.

venBio Select Advisor LLC

(9.1689%)

since

2025/06/30

4.

Vanguard Group Inc

(7.8602%)

since

2025/06/30

5.

Bvf Inc

(7.6964%)

since

2025/06/30

6.

FMR Inc

(7.5974%)

since

2025/06/30

7.

Wellington Management Company LLP

(7.5136%)

since

2025/06/30

8.

BlackRock Inc

(5.802%)

since

2025/06/30

9.

Siren, L.L.C.

(4.7948%)

since

2025/06/30

10.

US Small-Cap Growth II Equity Comp

(4.058%)

since

2025/06/30

11.

T. Rowe Price New Horizons

(3.7277%)

since

2025/07/31

12.

Vanguard Health Care Inv

(3.3386%)

since

2025/06/30

13.

Fidelity Growth Compy Commingled Pl S

(3.2949%)

since

2025/07/31

14.

Vanguard Total Stock Mkt Idx Inv

(2.6272%)

since

2025/07/31

15.

Fidelity Growth Company Fund

(2.2955%)

since

2025/07/31

16.

State Street Corp

(2.1741%)

since

2025/06/30

17.

Vanguard Small Cap Index

(2.027%)

since

2025/07/31

18.

Capital Research Global Investors

(1.7653%)

since

2025/06/30

19.

T. Rowe Price Health Sciences

(1.6853%)

since

2025/07/31

20.

Geode Capital Management, LLC

(1.6687%)

since

2025/06/30

21.

iShares Russell 2000 ETF

(1.5776%)

since

2025/08/31

22.

American Funds SMALLCAP World A

(1.5558%)

since

2025/06/30

23.

Vanguard Explorer Inv

(1.3677%)

since

2025/06/30

24.

Driehaus Capital Management LLC

(1.3062%)

since

2025/06/30

25.

T. Rowe Price New Horizons Tr-A

(1.3032%)

since

2025/06/30

26.

Jennison Associates LLC

(1.1539%)

since

2025/06/30

27.

UBS Asset Mgmt Americas Inc

(1.1454%)

since

2025/06/30

28.

Vanguard Small Cap Growth Index Inv

(1.1444%)

since

2025/07/31

29.

Redmile Group, LLC

(1.1235%)

since

2025/06/30

30.

Merck & Co Inc

(1.08%)

since

2025/06/30

31.

COMMODORE CAPITAL LP

(1.049%)

since

2025/06/30

32.

Deerfield Management Co

(0.9133%)

since

2025/06/30

33.

T. Rowe Price Integrated US SmCapGrEq

(0.7983%)

since

2025/06/30

34.

Dimensional Fund Advisors, Inc.

(0.7879%)

since

2025/06/30

35.

Eventide Healthcare & Life Sciences I

(0.7874%)

since

2025/06/30

36.

Vanguard Institutional Extnd Mkt Idx Tr

(0.78%)

since

2025/07/31

37.

T. Rowe Price Integrated US Sm Gr Eq

(0.7496%)

since

2025/07/31

38.

PGIM Jennison Health Sciences Z

(0.7322%)

since

2025/07/31

39.

Jennison Health Sciences Equity

(0.7322%)

since

2025/06/30

40.

SPDR® S&P Biotech ETF

(0.6839%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-09-30

EPS Actual

-0.94

EPS Estimate

-0.8613

EPS Difference

-0.0787

Surprise Percent

-9.1374%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(3)
Defensive
Highly Defensive(7)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(1)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(2.5)
Value
Overpriced(3)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.